Clinical Trials Browser

NIH × Leukemia, Myelomonocytic, Chronic × CTLA-4 Antigen × Clear all

NCT01757639 2018-03-21

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic